Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVG/r versus RAL in treatment-experienced HIV-1 infected adults
2007-004225-26Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elvitegravir and raltegravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Primary virologic efficacy. Started Jun 2008; status: completed.
02
Drugs
elvitegravirraltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-004225-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004225-26.